Vanda Pharmaceuticals Inc.

VNDANASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
6.01 USD
↗ 0.16 (2.74%)AT CLOSE (11:59 AM EDT)
6.02
↗ 0.01 (0.17%)
POST MARKET (AS OF 07:40 PM EDT)
Post Market
AS OF 07:40 PM EDT
6.02
↗ 0.01 (0.17%)
🔴Market: CLOSED

Shares of Vanda Pharmaceuticals Inc. (VNDA) are trading at $6.01. Technicals currently rate "Neutral" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bullish Golden Cross on the moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 26, 2026.

Open?$5.84
High?$6.03
Low?$5.84
Prev. Close?$5.85
Volume?1.5M
Avg. Volume?961.7K
VWAP?$5.94
Rel. Volume?1.59x
Bid / Ask
Bid?$5.14 × 100
Ask?$7.00 × 100
Spread?$1.86
Midpoint?$6.07
Valuation & Ratios
Market Cap?361.4M
Shares Out?60.1M
Float?53.8M
Float %?89.5%
P/E Ratio?N/A
P/B Ratio?1.29
EPS?-$3.98
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Themes
Biotech - Drug Development›Neuroscience & CNSBiotech - Drug Development›Rare Disease Therapeutics
Employees
533
Market Cap
351.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.vandapharma.com
Listed
2006-04-12
Address
2200 PENNSYLVANIA AVE NW
WASHINGTON, DC 20037
Phone: 202-734-3400
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
2
Momentum?
79
Short Sent.?
54
Piotroski F-Score?3/9Weak
Altman Z-Score?-0.29Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.99%High
Short Interest?7.0M
Days to Cover?7.8
Free Float53.8M
Avg Daily Volume898.5K
Settlement Date2026-06-15
Financial Health
Current Ratio?2.16Strong
Quick Ratio?2.15Strong
Cash Ratio?0.40Low
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.29CHEAP▾
P/S?
Peers
100
S&P
75
1.66CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.1CHEAP▾
EV/Sales?
Peers
100
S&P
85
1.43CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-85.3%WEAK▾
ROA?
S&P
3
-55.3%WEAK▾
Cash Flow & Enterprise
FCF?$-127296000
Enterprise Value?$311.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist